Celyad Oncology SA - ADR Peer Comparison
$0.52
$-0.03
(-5.42%)
As on 20-Jul-2023 09:30EDT
Market cap
$14 Mln
Revenue (TTM)
$-- Mln
P/E Ratio
--
P/B Ratio
0.7
Div. Yield
0 %
Edit
| Celyad Oncology SA - ADR | Nanobiotix (NBTX) | Galapagos NV - ADR | Inventiva Sa (IVA) | DBV Technologies S.A. - ADR | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
14 | 2,213 | 1,862 | 1,106 | 914 |
Revenue (€ Mln) |
-- | 30 | 1,044 | 4 | -- |
Net Profit (€ Mln) |
-40.94 | -23.96 | 488.78 | -340.16 | -175.85 |
Net Margin (%) |
-- | -- | 46.83 | -540.52 | -- |
RoE (%) |
-170.72 | 31.91 | 15.95 | 501.41 | -106.84 |
Price to Earnings |
-- | -- | 3.18 | -- | -- |
Price-To-Book |
0.69 | 65.02 | 0.49 | 2.10 | 5.59 |
Income Statement (€ Mln)
| Celyad Oncology SA - ADR | Nanobiotix (NBTX) | Galapagos NV - ADR | Inventiva Sa (IVA) | DBV Technologies S.A. - ADR | |
|---|---|---|---|---|---|
|
Operating Revenue
|
0.00 | 4.78 | 241.25 | 12.18 | 4.84 |
|
Cost of Revenue
|
0.00 | 0.99 | 12.08 | 1.00 | 20.30 |
|
Gross Profit
|
0.00 | 4.78 | 241.25 | 12.18 | 4.84 |
|
Operating Expenses
|
20.26 | 51.48 | 372.31 | 69.29 | 101.48 |
|
Operating Profit (EBIT)
|
-40.86 | -46.70 | -131.06 | -57.11 | -96.63 |
|
Other Income
|
-- | -- | -- | -- | -- |
|
Profit before Tax
|
-40.87 | -57.03 | -70.85 | -54.29 | -96.20 |
|
Provision for Tax
|
0.07 | 0.01 | 0.57 | -0.02 | 0.07 |
|
Profit after Tax (Net Income)
|
-40.94 | -57.04 | -217.99 | -54.27 | -96.27 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Consolidated Profit
|
-- | -57.04 | -217.99 | -- | -96.27 |
Liabilities (€ Mln)
| Celyad Oncology SA - ADR | Nanobiotix (NBTX) | Galapagos NV - ADR | Inventiva Sa (IVA) | DBV Technologies S.A. - ADR | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
4.32 | -27.05 | 2,526.03 | 45.48 | 194.45 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Non-Current Liabilities
|
4.97 | 48.88 | 1,685.79 | 39.83 | 22.54 |
|
Current Liabilities
|
10.43 | 37.94 | 522.54 | 30.70 | 29.52 |
|
Total Liabilities
|
19.72 | 59.77 | 4,734.35 | 116.00 | 246.52 |
Assets (€ Mln)
| Celyad Oncology SA - ADR | Nanobiotix (NBTX) | Galapagos NV - ADR | Inventiva Sa (IVA) | DBV Technologies S.A. - ADR | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
4.89 | 7.41 | 497.50 | 9.62 | 23.44 |
|
Current Assets
|
14.83 | 52.36 | 4,236.85 | 106.38 | 223.07 |
|
Total Assets
|
19.72 | 59.77 | 4,734.35 | 116.00 | 246.52 |
|
Total Debt*
|
0.26 | 53.17 | 21.90 | 34.51 | 10.03 |
|
Net Current Assets
|
4.40 | 14.42 | 3,714.31 | 75.68 | 193.55 |
Cashflow (€ Mln)
| Celyad Oncology SA - ADR | Nanobiotix (NBTX) | Galapagos NV - ADR | Inventiva Sa (IVA) | DBV Technologies S.A. - ADR | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-28.01 | -37.10 | -500.54 | -44.93 | -55.70 |
|
Cash Flow from Investing Activities
|
-- | 0.14 | -1,245.51 | 8.87 | -0.10 |
|
Cash from Financing Activities
|
3.24 | -5.65 | -1.49 | 37.27 | 194.10 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Celyad Oncology SA - ADR | Nanobiotix (NBTX) | Galapagos NV - ADR | Inventiva Sa (IVA) | DBV Technologies S.A. - ADR | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-161.03 | -115.31 | -8.36 | -60.65 | -61.29 |
|
ROE (%)
|
-170.72 | 44,738.04 | -8.43 | -80.80 | -65.61 |
|
ROA (%)
|
-82.15 | -70.62 | -4.39 | -45.61 | -49.01 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
-- | -1,194.33 | -90.36 | -445.64 | -1,987.49 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| Celyad Oncology SA - ADR | Nanobiotix (NBTX) | Galapagos NV - ADR | Inventiva Sa (IVA) | DBV Technologies S.A. - ADR | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-- | 0.80 | -0.50 | 1.90 | -0.15 |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
-54.40 | -21.36 | -73.81 | -9.34 | 1.57 |
|
EPS Growth (%)
|
-- | -0.21 | -0.76 | -0.03 | 0.42 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Celyad Oncology SA - ADR | Nanobiotix (NBTX) | Galapagos NV - ADR | Inventiva Sa (IVA) | DBV Technologies S.A. - ADR | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-- | -2.24 | -13.40 | -3.45 | -1.49 |
|
Price / Book Value
|
-- | -4.73 | 1.16 | 4.12 | 0.74 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
0.65 | -3.10 | -297.10 | -2.42 | 0.66 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Celyad Oncology SA - ADR | Nanobiotix (NBTX) | Galapagos NV - ADR | Inventiva Sa (IVA) | DBV Technologies S.A. - ADR | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.06 | -1.97 | 0.01 | 0.76 | 0.05 |
|
Short term debt to equity ratio
|
0.03 | -0.17 | 0.00 | 0.13 | 0.05 |
|
Current Ratio
|
1.42 | 1.38 | 8.11 | 3.47 | 7.56 |
|
Quick Ratio
|
-- | 1.30 | 8.01 | 3.45 | 7.47 |
|
Interest Coverage
|
-207.40 | -7.83 | -6.74 | -80.78 | -226.30 |
Operating Efficiency Ratios
| Celyad Oncology SA - ADR | Nanobiotix (NBTX) | Galapagos NV - ADR | Inventiva Sa (IVA) | DBV Technologies S.A. - ADR | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
-- | 59.51 | 32.06 | 2.29 | 231.21 |
|
Asset Turnover
|
0.00 | 0.06 | 0.05 | 0.10 | 0.02 |
|
Receivable days
|
-- | 257.59 | 155.90 | 177.93 | 1,668.88 |
|
Inventory Days
|
-- | -11.50 | 1,111.17 | 140.41 | -272.21 |
|
Payable days
|
-- | 1,667.73 | 4,045.93 | 6,233.29 | 233.04 |
|
Cash Conversion Cycle
|
-- | -1,421.63 | -2,778.86 | -5,914.95 | 1,163.64 |
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
